Millipore Sigma Vibrant Logo

539648 Staurosporine, N-Benzoyl

A cell-permeable Staurosporine derivative that displays antitumor properties.

Staurosporine, N-Benzoyl: Ficha de datos de seguridad (MSDS o SDS), certificado de análisis y de calidad (CoA y CoQ), expedientes, folletos y otros documentos disponibles.

Sinónimos: PKG Inhibitor IX, N-Benzoylstaurosporine, CGP 41 251, PKC412, PDGFR Tyrosine Kinase Inhibitor X

Primary Target: PKC (α, β and γ), PDGFRβ, VEGFR2, Syk, PKCη, PKCδ, Flk-1, Flt3, Cdk1/B, PKA, c-Kit, c-Fgr, c-Src, VEGFR1, and EGFR
View Products on Sigmaaldrich.com
539648
Ver precios y disponibilidad

Descripción

Replacement Information

Tabla espec. clave

CAS #Empirical Formula
120685-11-2C₃₅H₃₀N₄O₄

Precios y disponibilidad

Número de referencia DisponiblidadEmbalaje Cant./Env. Precio Cantidad
539648-1MG
Comprobando disponibilidad...
—
Disponibilidad a confirmar Disponibilidad a confirmar
Ingrese cantidad 
Suspendido
Cantidades limitadas disponibles
Debe confirmarse disponibilidad
    El resto: se avisará
      El resto: se avisará
      Se avisará
      Póngase en contacto con el Servicio de Atención al Cliente
      Contact Customer Service

      		 Ampolla de plást. 1 mg
      Recuperando precio...
      No pudo obtenerse el precio
      La cantidad mínima tiene que ser múltiplo de
      Maximum Quantity is
      Al finalizar el pedido Más información
      Ahorró ()
       
      —
      Solicitar precio
      		 —
      Description
      OverviewA cell-permeable Staurosporine (Cat. No. 569397) derivative that displays antitumor properties. Acts as a broad-spectrum, reversible, and ATP-competitive inhibitor of PKC (α, β and γ), PDGFRβ, VEGFR2, Syk, PKCη, PKCδ, Flk-1, Flt3, Cdk1/B, PKA, c-Kit, c-Fgr, c-Src, VEGFR1, and EGFR (IC50 = 22 nM, 50 nM, 86 nM, 95 nM, 160 nM, 330 nM, 390 nM, 528 nM, 570 nM, 570 nM, 600 nM, 790 nM, 800 nM, 912 nM, and 1.0 µM, respectively). At higher concentrations, also inhibits Ins-R and IGF-1R (IC50 = 10 µM). Shown to potently inhibit the proliferation of Ba/F3 cells expressing constitutively active Flt3 (IC50 < 10 nM).
      Catalogue Number539648
      Brand Family Calbiochem®
      SynonymsPKG Inhibitor IX, N-Benzoylstaurosporine, CGP 41 251, PKC412, PDGFR Tyrosine Kinase Inhibitor X
      References
      ReferencesWeisberg, E., et al. 2002. Cancer Cell 1, 433.
      Fabbro, D., et al. 2000. Anticancer Drug Des. 15, 17.
      Meyer, T., et al. 1999. Int. J. Cancer 81, 669.
      Meyer, T., et al. 1989. Int. J. Cancer 43, 851.
      Product Information
      CAS number120685-11-2
      ATP CompetitiveY
      FormTan solid
      Hill FormulaC₃₅H₃₀N₄O₄
      Chemical formulaC₃₅H₃₀N₄O₄
      ReversibleY
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetPKC (α, β and γ), PDGFRβ, VEGFR2, Syk, PKCη, PKCδ, Flk-1, Flt3, Cdk1/B, PKA, c-Kit, c-Fgr, c-Src, VEGFR1, and EGFR
      Primary Target IC<sub>50</sub>22 nM, 50 nM, 86 nM, 95 nM, 160 nM, 330 nM, 390 nM, 528 nM, 570 nM, 570 nM, 600 nM, 790 nM, 800 nM, 912 nM, and 1.0 µM against primary targets in the order listed
      Purity≥98% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage -20°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Número de referencia GTIN
      539648-1MG 04055977194838

      Documentation

      Staurosporine, N-Benzoyl Ficha datos de seguridad (MSDS)

      Título

      Ficha técnica de seguridad del material (MSDS) 

      Staurosporine, N-Benzoyl Certificados de análisis

      CargoNúmero de lote
      539648

      Referencias bibliográficas

      Visión general referencias
      Weisberg, E., et al. 2002. Cancer Cell 1, 433.
      Fabbro, D., et al. 2000. Anticancer Drug Des. 15, 17.
      Meyer, T., et al. 1999. Int. J. Cancer 81, 669.
      Meyer, T., et al. 1989. Int. J. Cancer 43, 851.
      Ficha técnica

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision06-February-2014 JSW
      SynonymsPKG Inhibitor IX, N-Benzoylstaurosporine, CGP 41 251, PKC412, PDGFR Tyrosine Kinase Inhibitor X
      DescriptionA cell-permeable Staurosporine (Cat. No. 569397) derivative that displays antitumor properties. Acts as a broad-spectrum, reversible, and ATP-competitive inhibitor of PKC (α, β and γ), PDGFRβ, VEGFR2, Syk, PKCη, PKCδ, Flk-1, Flt3, Cdk1/B, PKA, c-Kit, c-Fgr, c-Src, VEGFR1, and EGFR (IC50 = 22 nM, 50 nM, 86 nM, 95 nM, 160 nM, 330 nM, 390 nM, 528 nM, 570 nM, 570 nM, 600 nM, 790 nM, 800 nM, 912 nM, and 1.0 µM, respectively). At higher concentrations, also inhibits Ins-R and IGF-1R (IC50 = 10 µM). Shown to potently inhibit the proliferation of Ba/F3 cells expressing constitutively active Flt3 (IC50 < 10 nM).
      FormTan solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number120685-11-2
      Chemical formulaC₃₅H₃₀N₄O₄
      Structure formulaStructure formula
      Purity≥98% by HPLC
      SolubilityDMSO (6 mg/ml)
      Storage Protect from light
      -20°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Toxicity Standard Handling
      ReferencesWeisberg, E., et al. 2002. Cancer Cell 1, 433.
      Fabbro, D., et al. 2000. Anticancer Drug Des. 15, 17.
      Meyer, T., et al. 1999. Int. J. Cancer 81, 669.
      Meyer, T., et al. 1989. Int. J. Cancer 43, 851.